Antiviral activity against Respiratory syncytial virus infected in human HEp-2 cells assessed as reduction in viral infection incubated for 60 hrs by MTT assay
Antiviral activity against Respiratory syncytial virus infected in human HEp-2 cells assessed as inhibition of virus infected cells induced lesion formation at 25 uM measured after 60 hrs by microscopic analysis
Antiviral activity against Respiratory syncytial virus Long infected in human HEp-2 cells assessed as reduction in viral infection incubated for 60 hrs by MTT assay
Antiviral activity against Respiratory syncytial virus Long infected in human A549 cells assessed as reduction in viral infection incubated for 60 hrs by MTT assay
Antiviral activity against Respiratory syncytial virus Long infected in African green monkey Vero cells assessed as reduction in viral infection incubated for 60 hrs by MTT assay
Antiviral activity against Respiratory syncytial virus A2 infected in human HEp-2 cells assessed as reduction in viral infection incubated for 60 hrs by MTT assay
Antiviral activity against Respiratory syncytial virus A2 infected in human A549 cells assessed as reduction in viral infection incubated for 60 hrs by MTT assay
Antiviral activity against Respiratory syncytial virus A2 infected in African green monkey Vero cells assessed as reduction in viral infection incubated for 60 hrs by MTT assay
Antiviral activity against Respiratory syncytial virus Long infected in human HEp-2 cells assessed as reduction in viral infection up to 50 uM treated 2 hpi measured after 60 hrs by MTT assay
Antiviral activity against Respiratory syncytial virus A2 infected in human HEp-2 cells assessed as reduction in viral infection up to 50 uM treated 2 hpi measured after 60 hrs by MTT assay
Antiviral activity against Respiratory syncytial virus infected in human HEp-2 cells assessed as inhibition of viral replication at 25 uM treated up to 14 hpi and measured after 60 hrs by MTT assay
Antiviral activity against Respiratory syncytial virus infected in human HEp-2 cells assessed as reduction in RSV-F gene expression at 25 uM measured after 24 to 60 hpi by RT-PCR analysis
Inhibition of RSV induced apoptosis in human HEp-2 cells assessed as early apoptotic cells at 25 uM measured after 60 hrs by Annexin V-FITC/PI staining based flow cytometry analysis (Rvb = 10.3%)
Inhibition of RSV induced apoptosis in human HEp-2 cells assessed as late apoptotic cells at 25 uM measured after 60 hrs by Annexin V-FITC/PI staining based flow cytometry analysis (Rvb = 20.2%)
Inhibition of RSV induced apoptosis in human HEp-2 cells assessed as early apoptotic cells at 50 uM measured after 60 hrs by Annexin V-FITC/PI staining based flow cytometry analysis (Rvb = 10.3%)
Inhibition of RSV induced apoptosis in human HEp-2 cells assessed as late apoptotic cells at 50 uM measured after 60 hrs by Annexin V-FITC/PI staining based flow cytometry analysis (Rvb = 20.2%)
Induction of apoptosis in human HEp-2 cells assessed as early apoptotic cells at 25 uM measured after 60 hrs by Annexin V-FITC/PI staining based flow cytometry analysis (Rvb = 0.1%)